| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2.71 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Cervical cancer prevention is based on primary prevention with vaccines againstHuman Papillomavirus (HPV) and secondary prevention by screening with High‐Risk‐HPV (Hr‐HPV) detection. Since 2017, cervical cancer screening in women aged25−60 years has been performed in Portugal using Hr‐HPV detection, followed bycytology in Hr‐HPV‐positive cases. Herein we report the prevalence of Hr‐HPVgenotypes and cytological abnormalities among 462 401 women (mean age:43.73 ± 10.79; median age: 45; range: 24−66 years) that participated in the RegionalCervical Cancer Screening Program of the Northern Region of Portugal, performedbetween August 2016 and December 2021. Overall, we describe a prevalence rateof 12.50% for Hr‐HPV varying from 20.76% at age 25% to 8.32% at age 64. The fivemost common Hr‐HPV genotypes identified were HPV‐68 (16.09%), HPV‐31(15.30%), HPV‐51 (12.96%), HPV‐16 (11.06%), and HPV‐39 (11.01%). Theprevalence of Hr‐HPV included in the nonavalent vaccine (HPV‐9valent) was55.00% ranging from 47.78% to 59.18% across different age groups.
Description
Keywords
Human papillomavirus Cervical cancer Genotyping Prevalence Screening Vaccine
Pedagogical Context
Citation
Rosário, Andreia; Saraiva Sousa, Ana; Marinho-Dias, Joana; Medeiros, R; Lobo, Cláudia; Leça, Luís; Coimbra, Nuno; Tavares, Fernando; Baldaque, Inês; Martins, Maria Gabriela; Monteiro, Paula; Henrique, Rui (2023). Impact of high‐risk human papilloma virus genotyping in cervical disease in the Northern region of Portugal: real‐world data from regional cervical cancer screening program. Journal of Medical Virology. ISSN 1096-9071. 95:1, p. 1-11
Publisher
WILEY